Clinical, histopathological features and related factors affecting survival results after surgery of cutaneous melanoma
Main Article Content
Abstract
This is a retrospective and prospective study on 130 cutaneous melanoma patients in stage 2,3 who were operated at K hospital from 2013 to 2019. Results:male/female 1.03, common age over 40 years old, lower limbs 46.9%, superficial spreading melanoma 52,3%, thickness > 2 mm 97.7%, Clark IV,V 80.8%, vertical growth phase 76.2 %, satellite 33.8%, ulceration 49.2%, lymphovascular/angiolymphatic invasion 20.8%, mitotic rate > 6/mm² 40.8%, sparse tumor infiltrating lymphocytes 46.2%, positive regional lymph nodes 48.5%, stage 2, 3 is 43.1%, 56.9%, respectively. Overall 5-year survival rate 47.1%. Adverse prognostic factors affect overall 5-years survival: nodular, acral lentiginous, increasing tumor thickness, high Clark level, vertical growth phase, satellite, ulceration, lymphovascualar/angiolymphatic invasion , high mitotic rate, decreasing tumor infiltrating lymphocytes, increasing number of regional lymph nodes metastases and upstage.
Article Details
Keywords
Cutaneous melanoma, prognostic factors, histopathology
References
2. Lê Đình Roanh. U hắc tố ác tính, giải phẫu bệnh học. Hà Nội: Nhà xuất bản Y học; 1998.
3. Marc Hurlbert. 2020 Melanoma mortality rates decreasing despite ongoing increase in incidence. Melanoma research Alliance2020.
4. Phạm Thị Hoàng Anh, Nguyễn Thị Hoài Nga, Trần Hồng Trường. Tình hình bệnh ung thư ở Hà Nội giai đoạn 1996-1999 Tạp chí y học thực hành. 2002:4-11.
5. Đào Tiến Lục. Nghiên cứu đặc điểm lâm sàng, mô bệnh học và một số yếu tố tiên lượng của ung thư hắc tố ác tính. Hà Nội: Luận văn bác sĩ nội trú, Trường đại học Y Hà Nội; 2001.
6. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(16):3622-3634.
7. Garbe C, Büttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75(10):2484-2491.
8. Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Japanese journal of clinical oncology. 2021;51(5):671-674.
9. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(14):2452-2459.
10. Clark WH, Jr., Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. Journal of the National Cancer Institute. 1989;81(24):1893-1904.
11. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78(3):427-432.
12. Xiaowei Xu MD, Phyllis A. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Human Pathology. 2008;39:901-909.
13. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Annals of surgical oncology. 2005;12(6):449-458.
14. Mandalà M, Galli F, Cattaneo L, et al. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. J Am Acad Dermatol. 2017;76(2):264-273.e262.